(Q43975777)

28 November 2017

title

Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression (English)

1 reference

28 November 2017

author

Carolyn Bolden-Watson

object named as

Carolyn Bolden-Watson

5

0 references

author name string

Karen L Weihs

1

1 reference

28 November 2017

Trisha L Houser

2

1 reference

28 November 2017

Sharyn R Batey

3

1 reference

28 November 2017

John A Ascher

4

1 reference

28 November 2017

Rafe M J Donahue

6

1 reference

28 November 2017

Alan Metz

7

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

28 November 2017

published in

Biological Psychiatry

1 reference

28 November 2017

volume

51

1 reference

28 November 2017

issue

9

1 reference

28 November 2017

page(s)

753-761

1 reference

Body weight gain induced by antipsychotic drugs: mechanisms and management

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Prescription medications: a modifiable contributor to obesity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Sertraline in the prevention of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Drugs that cause weight gain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Three-year outcomes for maintenance therapies in recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Acute and Long-Term Bupropion Therapy: Response and Side Effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

The assessment of anxiety states by rating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Development of a Rating Scale for Primary Depressive Illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Long-term nature of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Recognition and management of depression in general practice: consensus statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Continuation drug therapy for major depressive episodes: how long should it be maintained?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Safety profile of sustained-release bupropion in depression: results of three clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

Bupropion sustained release versus paroxetine for the treatment of depression in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2801%2901317-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(01)01317-8

1 reference

28 November 2017

1 reference